Details der Publikation - A Phase 3 trial of perioperative pembrolizumab for cisplatin-ineligible patients with MIBC

A Phase 3 trial of perioperative pembrolizumab for cisplatin-ineligible patients with MIBC : A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Cisplatin-ineligible Participants with Muscle-Invasive Bladder Cancer (KEYNOTE-905/EV-303) - A Phase 3 trial of perioperative pembrolizumab for cisplatin-ineligible patients with MIBC

Medienart:	Klinische Studie

Erscheinungsjahr:	2021
Erschienen:	2021

Enthalten in:	WHO International Clinical Trials Registry Platform - (2021) vom: 08. Nov. Zur Gesamtaufnahme - year:2021

Sprache:	Englisch

Links:	Volltext [kostenfrei]

Themen:	610 Medical Condition: Muscle-invasive Bladder Cancer (MIBC) MedDRA version: 21.1Level: LLTClassification code 10022877Term: Invasive bladder cancerSystem Organ Class: 100000004864;Therapeutic area: Diseases [C] - Cancer [C04] Phase: Phase 3 Recruitment Status: Authorised-recruitment may be ongoing or finished Study Type: Interventional

Anmerkungen:	WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 29-03-2019, Last updated: 2022-11-24

ICTRP ID:	EUCTR2018-003809-26-IE MK-3475-905 2018-003809-26-SE

Förderinstitution / Projekttitel:

PPN (Katalog-ID):	WHO004352181

Internformat


LEADER	01000caa a22002652 4500
001	WHO004352181
003	DE-627
005	20230425175141.0
007	cr uuu---uuuuu
008	210507s2021 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)WHO004352181
035			\|a (UBBS_Klinische_Studien_WHO)EUCTR2018-003809-26-IE
035			\|a (UBBS_Klinische_Studien_WHO)MK-3475-905
035			\|a (UBBS_Klinische_Studien_WHO)2018-003809-26-SE
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
245	1	0	\|a A Phase 3 trial of perioperative pembrolizumab for cisplatin-ineligible patients with MIBC \|b A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Cisplatin-ineligible Participants with Muscle-Invasive Bladder Cancer (KEYNOTE-905/EV-303) - A Phase 3 trial of perioperative pembrolizumab for cisplatin-ineligible patients with MIBC
264		1	\|c 2021
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 29-03-2019, Last updated: 2022-11-24
650		4	\|a Medical Condition: Muscle-invasive Bladder Cancer (MIBC) MedDRA version: 21.1Level: LLTClassification code 10022877Term: Invasive bladder cancerSystem Organ Class: 100000004864;Therapeutic area: Diseases [C] - Cancer [C04]
650		4	\|a Study Type: Interventional
650		4	\|a Phase: Phase 3
650		4	\|a Recruitment Status: Authorised-recruitment may be ongoing or finished
650		4	\|a 610
773	0	8	\|i Enthalten in \|t WHO International Clinical Trials Registry Platform \|g (2021) vom: 08. Nov.
773	1	8	\|g year:2021 \|g day:08 \|g month:11
856	4	0	\|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-003809-26 \|z kostenfrei \|3 Volltext
912			\|a GBV_CTG
912			\|a SSG-OLC-PHA
951			\|a AR
952			\|j 2021 \|b 08 \|c 11

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände